NEW YORK (GenomeWeb News) – Qiagen said after the close of the market on Wednesday it has entered into an agreement with Eli Lilly to develop companion diagnostics for the drug firm's investigational and approved medicines across all therapeutic areas.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.